Calquence combination improved PFS in 1L MCL
02 May 2024 Calquence combination regimen demonstrated statistically significant and clinically meaningful improvement in progression-free survival in 1st-line mantle cell lymphoma in ECHO Phase III trial First BTK inhibitor to show favourable trend in overall survival vs. standard-of-care chemoimmunotherapy in this setting Positive high-level results from an interim analysis of the ECHO Phase III trial showed AstraZeneca's Calquence (acalabrutinib) in combination with standard-of-care chemoimmunotherapy, bendamustine and rituximab, demonstrated a statistically significant and